Thursday, 23 Jan 2020

You are here

RheumNow Podcast- Knee Pain Knockout (1.10.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

  1. UK study of 2701 Early arthritis pts Dx in 3 different eras finds that from those dx in 2010, 59% were estimated to reach low disease activity compared with 48% with diagnosis in 2002 and 32% with diagnosis in 1990. http://bit.ly/2N9cy7u 
  2. Study of 1054 adults with septic bone, joint, prosthetic infections shows that 6 weeks of oral antibiotic therapy cost less and was noninferior to IV antibiotic therapy (success rate ~85% at 1 year) while being >20% cheaper https://t.co/MYNxAWT1GT
  3. Misuse and abuse of Gabapentin in US? Between 2003-2016 there were 260 million gabapentinoid visits. Annual use nearly quadrupled from 2003 to 2016 (mostly PCPs 46%). Nearly half w/ concurrent opioids (32.9%) or benzodiazepines (15.3%). https://t.co/Wnja1mkDQo
  4. Systematic literature of biologic Rx of dactylitis & enthesitis in Psoriatic arthritis. 18 trials, 6981 patients showed that TNF inhib & ustekinumab, secukinumab, ixekizumab were 2-3 fold significantly better than PBO at resolution of dactylitis by Wk 24. https://t.co/HlQcw5cXsN
  5. 301 fibromyalgia #FM pts randomized to receive active‐TENS or placebo‐TENS or no‐TENS to use at home 2h/day for 4 wks. Active TENS had greater reduction in pain & fatigue vs placeboAND better global improvement (70% vs. 31%, p<0.0001) https://t.co/AH84DxlTo3
  6. CORRONA registry 880 RA pts developed a solid cancer. 42% taking bDMARD/tsDMARD; 5% switched biologics w/in 36 mos & 10% started a new biologic- w/ most changing to a TNFi (53%). ACR guidelines say to Rx regardless of solid tumor https://t.co/pPgnYNdT7Q
  7. high-dose trivalent inactivated influenza vaccine (HD-TIV) was studied in 696 RA patients compared to standard-dose quadrivalent flu vaccine - Seroconversion was 3 fold higher w/ HD-TIV, no differences in side effects and no increase in RA flares https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30094-3/fulltext
  8. Claims data from RA patients (n = 12,182), shows that screening for hyperlipidemia was suboptimal (compared to Diabetes pts), Those seeing a PCP and Rheum were 36% more likely to be screened. https://t.co/j661loTDGk
  9. Genicular Artery Embolization to Treat Osteoarthritis Knee Pain   
  10. Taltz Shines in Non-Radiographic Axial Spondyloarthritis  
  11. ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis  
  12. RheumNow.Live – March 13-15, 2020

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

QD Clinic - "I Don't Know Why I'm Here" Consult

QD Clinic - Lessons from the clinic The Consult that shows up without a cause - and what to do?

CDC: 15% of US Adults are Physically Inactivie

All states and territories had more than 15% of adults who were physically inactive and this estimate ranged from 17.3 to 47.7%,  according to new state maps of adult physical inactivity prevalence released today by the Centers for Disease Control and Prevention (CDC).

RheumNow Podcast- The Down Side of Steroids (1.17.20)

Dr. Jack Cush reviews the journal reports and news from RheumNow.com. Be sure to register for RheumNow Live 3/13/2020 in Fort Worth Rheumnow.live.

2019 Rheumatology Year in Review

2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology.   Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond. 

RheumNow Podcast - 2019 Rheumatology Year in Review

Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.